8-K: Brainstorm Secures $279K via High-Cost Convertible Notes

Brainstorm Cell Therapeutics Inc. entered into three separate agreements to issue convertible promissory notes totaling $329,175 in principal, securing approximately $279,000 in net proceeds after significant discounts and fees.

Summary

• Brainstorm Cell Therapeutics Inc. (the "Company") entered into three separate securities purchase transactions to issue convertible promissory notes to institutional investors.
• The total principal amount of the notes issued is $329,175.00.
• The aggregate cash proceeds received by the Company from these transactions, after accounting for original issue discounts and legal/due diligence fees, is approximately $279,000.00.
• The notes carry significant original issue discounts and one-time interest charges, ranging from 10% to 12%.
• All notes are unsecured and include provisions for conversion into common stock at a discount to market price, typically upon an Event of Default.
• Default interest rates are high (22%), and default payment penalties are substantial (150% to 175% of outstanding amounts).
• The notes include various covenants and events of default that provide strong protections for the noteholders, such as maintaining public information, market capitalization thresholds, and restrictions on future financings.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the high cost of capital, significant dilution potential, stringent covenants, and punitive default terms associated with these convertible notes. While the company secured needed capital, the terms reflect a distressed financing situation that is highly unfavorable to existing shareholders and limits future financial flexibility.

Positives

• Secured approximately $279,000 in immediate capital, providing working capital for the Company.
• The notes are unsecured, meaning no specific assets are pledged as collateral.
• The note with Vanquish Funding Group Inc. contemplates additional tranches of up to $2,000,000.00 in aggregate financing, subject to further agreement.

Negatives

• High cost of capital due to significant original issue discounts (e.g., $12,300 on $94,300 principal, $12,375 on $94,875 principal, $14,000 on $140,000 principal) and one-time interest charges (10% to 12%).
• Effective cash proceeds are significantly lower than the principal amounts due to OID and upfront fees paid to lenders (e.g., $82,000 received for $94,300 principal, $80,000 for $94,875 principal, $117,000 for $140,000 principal).
• Conversion features are highly dilutive, allowing noteholders to convert into common stock at a significant discount to market price (65% or 75% of recent lowest trading prices) upon an Event of Default.
• Substantial default penalties (150% to 175% of outstanding principal and accrued interest) further burden the Company in case of default.
• The Auctus Fund note includes a "Most Favored Nation" clause, which could force the Company to offer equally favorable terms to Auctus if it secures better terms in future financings.
• The Auctus Fund note prohibits the Company from entering into "Variable Rate Transactions" and from issuing or announcing new securities for 30 days, limiting future financing flexibility.
• The Auctus Fund note allows the holder to demand repayment of up to 50% of future cash proceeds (above an initial $500,000 aggregate from equity/debt issuance), potentially impacting the Company's liquidity.
• The Quick Capital note requires Holder's consent for prepayment, limiting the Company's ability to refinance on better terms.
• The Vanquish Funding note has a relatively short maturity date of October 30, 2026, requiring quick repayment or refinancing.

Risks

• Significant Dilution Risk: Conversion features at discounted market prices, especially upon an Event of Default, pose a substantial risk of dilution for existing shareholders.
• High Default Risk: The numerous and stringent Events of Default clauses across all notes (e.g., failure to pay, failure to issue shares, breach of covenants, delisting, failure to comply with Exchange Act, market capitalization below $500,000 for Auctus) increase the likelihood of default.
• Liquidity Risk: The requirement for amortization payments and the potential for noteholders to demand repayment from future cash proceeds (Auctus Fund) could strain the Company's cash flow.
• Refinancing Risk: The high cost of these notes and restrictive covenants (e.g., prohibition on variable rate transactions, MFN clauses) may make it difficult or more expensive for the Company to secure future financing on favorable terms.
• Market Perception Risk: Issuing multiple high-cost convertible notes with dilutive terms often signals financial distress to the market, potentially negatively impacting share price and investor confidence.
• Operational Constraints: Covenants restricting asset sales outside the ordinary course of business, certain loans/advances, and changes in business nature (without holder consent) could limit strategic flexibility.
• Legal and Regulatory Risk: Failure to comply with SEC reporting, transfer agent obligations, or other legal requirements can trigger an Event of Default.
• Going Concern Risk: The nature of these financings suggests underlying financial challenges, despite a clause stating that disclosure of going concern ability is not an admission of inability to pay debts.

Future Outlook

The Company intends to use the proceeds from these financings for general working capital and business development purposes. The agreements include provisions for potential future tranches of financing (up to $2,000,000 with Vanquish Funding Group Inc.) subject to further agreement, indicating a potential need for additional capital.

Management Comments

• The Company has performed, satisfied and complied in all material respects with all the covenants, agreements and conditions under each of the Transaction Documents to be performed, satisfied or complied with by the Company.
• The Company shall continue to perform each and every covenant, agreement and condition set forth in each of the Transaction Documents and this Note, and continue to be bound by each and all of the terms and provisions thereof and hereof.
• The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby.
• The Company acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees that the Holder shall be entitled to an injunction or injunctions restraining, preventing or curing any breach and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

Industry Context

The issuance of multiple high-cost convertible notes with significant discounts and stringent default provisions is characteristic of financing sought by companies facing liquidity challenges or operating in high-risk sectors, such as early-stage biotechnology or those with uncertain revenue streams. These terms suggest that traditional debt or equity financing may be difficult to obtain, reflecting a higher perceived risk by investors. The dilutive nature of these instruments, particularly the conversion at a discount to market price, is a common feature in such 'death spiral' or 'toxic' financings, often seen in companies with volatile stock prices or those in urgent need of capital.

Comparison to Industry Standards

• The original issue discounts (e.g., 13-15% of principal) and one-time interest charges (10-12%) are significantly higher than typical corporate debt, even for high-yield bonds, indicating a very high cost of capital.
• Conversion prices set at a discount to the lowest trading price over a look-back period (e.g., 65% of the lowest 10-day or 15-day trading price, 75% of the lowest 20-day trading price) are highly dilutive and are generally considered unfavorable compared to standard convertible debt which often converts at a premium or fixed price.
• The 4.99% beneficial ownership limitation is standard for institutional investors to avoid triggering Schedule 13D filing requirements, but the overall terms are aggressive.
• The 150-175% default payment penalties are substantially higher than typical default interest rates or penalties in more conventional financing arrangements, reflecting the high-risk nature of these loans.
• The inclusion of "Most Favored Nation" clauses and prohibitions on "Variable Rate Transactions" (Auctus Fund) are common in distressed financings to protect the lender's position against future, potentially more favorable, financings by the company.
• The requirement for D&O insurance (Auctus Fund) is a standard corporate governance practice, but its inclusion as a specific covenant in a debt agreement highlights the lender's concern for management accountability and potential litigation.
• The ability for the Auctus Fund holder to demand repayment from future cash proceeds (above a $500,000 threshold) is an aggressive term, more typical of secured debt or highly structured financings for companies with limited alternative funding options.

Corporate Governance

Stakeholder Impact

• Shareholders: Face significant potential dilution from the conversion features of the notes, especially if the stock price declines or an Event of Default occurs. The high cost of capital also reduces shareholder value.
• Creditors: The notes are unsecured, placing them behind any secured creditors. However, the aggressive default terms and penalties provide strong protection for these specific noteholders.
• Management/Employees: The company's financial constraints and the need to comply with stringent covenants could impact operational decisions and resource allocation. The D&O insurance requirement reflects a focus on management accountability.

Next Steps

• The Company must make scheduled amortization payments on the notes, with the first payments due in June and July 2026.
• The Company must maintain compliance with all covenants and avoid Events of Default to prevent accelerated repayment and further dilution.
• The Company may pursue additional tranches of financing with Vanquish Funding Group Inc. up to $2,000,000.00, subject to further agreement.
• The Company must purchase director and officer insurance within 60 calendar days of the Auctus Fund closing.
• The Company must maintain its listing on a principal market and comply with 1934 Act reporting requirements.

Key Dates

Recommendation

The terms of these convertible notes are highly unfavorable, indicating severe financial distress for Brainstorm Cell Therapeutics Inc. The substantial original issue discounts, high one-time interest charges, and punitive default penalties (150-175% of outstanding amounts) represent an extremely high cost of capital. The conversion features, allowing conversion at a significant discount to market prices (65-75% of recent lows) upon an Event of Default, pose an immediate and severe dilution risk to existing shareholders. Furthermore, the numerous and broad Events of Default clauses, including a low market capitalization threshold for one note, make default highly probable. Restrictive covenants, such as the 'Most Favored Nation' clause, prohibitions on certain future financings, and the ability for a noteholder to demand repayment from future cash proceeds, severely limit the Company's financial and strategic flexibility. These 'toxic' financing terms typically lead to significant shareholder value destruction and signal a precarious financial position, making the stock a strong sell.

Keywords

Convertible Promissory Note, SEC Filing, 8-K, Brainstorm Cell Therapeutics, BCLI, Unsecured Debt, Original Issue Discount, Dilution, Default Risk, Capital Raise, Financial Distress, Corporate Finance, Equity Line of Credit, Securities Purchase Agreement, Accredited Investor, OTC Markets